ID   NB4
AC   CVCL_0005
SY   NB-4; NB.4
DR   BTO; BTO:0002136
DR   CLO; CLO_0007947
DR   EFO; EFO_0002798
DR   MCCL; MCC:0000350
DR   CLDB; cl3643
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03470835
DR   BioSample; SAMN10988571
DR   CCLE; NB4_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   Cell_Model_Passport; SIDM00428
DR   ChEMBL-Cells; CHEMBL3308423
DR   ChEMBL-Targets; CHEMBL614188
DR   CLS; 300299/p11500_NB-4
DR   CLS; 300299-SF/p11500_NB-4
DR   Cosmic; 787463
DR   Cosmic; 850391
DR   Cosmic; 922661
DR   Cosmic; 924050
DR   Cosmic; 975285
DR   Cosmic; 981582
DR   Cosmic; 996313
DR   Cosmic; 1012107
DR   Cosmic; 1037664
DR   Cosmic; 1070692
DR   Cosmic; 1078721
DR   Cosmic; 1089522
DR   Cosmic; 1127257
DR   Cosmic; 1181601
DR   Cosmic; 1523826
DR   Cosmic; 1524838
DR   Cosmic; 1601063
DR   Cosmic; 1604862
DR   Cosmic; 1779130
DR   Cosmic; 2036677
DR   Cosmic; 2089653
DR   Cosmic; 2131548
DR   Cosmic; 2306227
DR   Cosmic; 2579202
DR   Cosmic-CLP; 1323913
DR   DepMap; ACH-000294
DR   DSMZ; ACC-207
DR   ENCODE; ENCBS032SIL
DR   ENCODE; ENCBS259AAA
DR   ENCODE; ENCBS390ENC
DR   GDSC; 1323913
DR   GEO; GSM236798
DR   GEO; GSM236834
DR   GEO; GSM472929
DR   GEO; GSM510512
DR   GEO; GSM510513
DR   GEO; GSM887349
DR   GEO; GSM888426
DR   GEO; GSM945252
DR   GEO; GSM945275
DR   GEO; GSM1374696
DR   GEO; GSM1374697
DR   GEO; GSM1446740
DR   GEO; GSM1670151
DR   IARC_TP53; 21530
DR   IARC_TP53; 21705
DR   LiGeA; CCLE_910
DR   LINCS_LDP; LCL-1084
DR   Lonza; 749
DR   NCBI_Iran; C515
DR   PharmacoDB; NB4_990_2019
DR   PRIDE; PXD000589
DR   PRIDE; PXD001610
DR   Wikidata; Q54907527
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   Patent=US5589345;
RX   PubMed=1453773;
RX   PubMed=1995093;
RX   PubMed=7630193;
RX   PubMed=9737686;
RX   PubMed=11704857;
RX   PubMed=12353268;
RX   PubMed=14504097;
RX   PubMed=15843827;
RX   PubMed=16408098;
RX   PubMed=22460905;
RX   PubMed=23325432;
RX   PubMed=23955599;
RX   PubMed=25894527;
RX   PubMed=25984343;
RX   PubMed=27397505;
RX   PubMed=30285677;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
WW   http://www.proteinatlas.org/learn/cellines
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/NB4_protocol.pdf
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: ENCODE project common cell types; tier 3.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2030.
CC   Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-1045.
CC   Doubling time: 36-40 hours (PubMed=1995093); 30 hours (PubMed=25984343); ~35-45 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: PML-RARA gene fusion (PubMed=12353268; PubMed=15843827).
CC   Sequence variation: Heterozygous for KRAS p.Ala18Asp (c.53C>A) (CCLE; Cosmic-CLP).
CC   Sequence variation: Homozygous for TP53 p.Arg248Gln (c.743G>A) (ClinVar=VCV000012356) (Cosmic-CLP).
CC   Omics: Cell surface proteome.
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=3.99%; Native American=0%; East Asian, North=4.75%; East Asian, South=0%; South Asian=0%; European, North=49.28%; European, South=41.98% (PubMed=30894373).
CC   Derived from sampling site: Bone marrow.
ST   Source(s): CLS; Cosmic-CLP; DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 9
ST   D18S51: 12,14
ST   D21S11: 28,33.2
ST   D3S1358: 15,17
ST   D5S818: 13
ST   D7S820: 10,13
ST   D8S1179: 10,14
ST   FGA: 21,22
ST   Penta D: 10,13
ST   Penta E: 7,13
ST   TH01: 7,9.3
ST   TPOX: 8,11
ST   vWA: 16,19
DI   NCIt; C3182; Acute promyelocytic leukemia with PML-RARA
DI   ORDO; Orphanet_520; Acute promyelocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   23Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 31
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   Patent=US5589345;
RA   Lanotte M., Berger R.;
RT   "Cultures of permanent lines of human promyelocytic cells and their
RT   uses for the screening of molecules utilizable in particular in the
RT   treatment of leukemias.";
RL   Patent number US5589345, 31-Dec-1996.
//
RX   PubMed=1453773;
RA   Duprez E., Ruchaud S., Houge G., Martin-Thouvenin V., Valensi F.,
RA   Kastner P., Berger R., Lanotte M.;
RT   "A retinoid acid 'resistant' t(15;17) acute promyelocytic leukemia
RT   cell line: isolation, morphological, immunological, and molecular
RT   features.";
RL   Leukemia 6:1281-1287(1992).
//
RX   PubMed=1995093; DOI=10.1182/blood.V77.5.1080.1080;
RA   Lanotte M., Martin-Thouvenin V., Najman S., Balerini P., Valensi F.,
RA   Berger R.;
RT   "NB4, a maturation inducible cell line with t(15;17) marker isolated
RT   from a human acute promyelocytic leukemia (M3).";
RL   Blood 77:1080-1086(1991).
//
RX   PubMed=7630193;
RA   Bruel A., Benoit G., De Nay D., Brown S., Lanotte M.;
RT   "Distinct apoptotic responses in maturation sensitive and resistant
RT   t(15;17) acute promyelocytic leukemia NB4 cells. 9-cis retinoic acid
RT   induces apoptosis independent of maturation and Bcl-2 expression.";
RL   Leukemia 9:1173-1184(1995).
//
RX   PubMed=9737686; DOI=10.1038/sj.leu.2401112;
RA   Zhang W., Ohnishi K., Shigeno K., Fujisawa S., Naito K., Nakamura S.,
RA   Takeshita K., Takeshita A., Ohno R.;
RT   "The induction of apoptosis and cell cycle arrest by arsenic trioxide
RT   in lymphoid neoplasms.";
RL   Leukemia 12:1383-1391(1998).
//
RX   PubMed=11704857; DOI=10.1038/sj.onc.1204863;
RA   Roussel M.J., Lanotte M.;
RT   "Maturation sensitive and resistant t(15;17) NB4 cell lines as tools
RT   for APL physiopathology: nomenclature of cells and repertory of their
RT   known genetic alterations and phenotypes.";
RL   Oncogene 20:7287-7291(2001).
//
RX   PubMed=12353268; DOI=10.1002/gcc.10117;
RA   Mozziconacci M.-J., Rosenauer A., Restouin A., Fanelli M., Shao W.,
RA   Fernandez F., Toiron Y., Viscardi J., Gambacorti-Passerini C.,
RA   Miller W.H. Jr., Lafage-Pochitaloff M.;
RT   "Molecular cytogenetics of the acute promyelocytic leukemia-derived
RT   cell line NB4 and of four all-trans retinoic acid-resistant
RT   subclones.";
RL   Genes Chromosomes Cancer 35:261-270(2002).
//
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric
RT   ALL with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23325432; DOI=10.1101/gr.147942.112;
RA   Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E.,
RA   Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A.,
RA   Crawford G.E., Absher D.M., Wold B.J., Myers R.M.;
RT   "Dynamic DNA methylation across diverse human cell lines and
RT   tissues.";
RL   Genome Res. 23:555-567(2013).
//
RX   PubMed=23955599; DOI=10.1038/ng.2731;
RA   Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y.,
RA   Yoshida K., Okuno Y., Bando M., Nakato R., Ishikawa S.,
RA   Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D.,
RA   Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K.,
RA   Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M.,
RA   Nakamaki T., Ishiyama K., Nolte F., Hofmann W.K., Miyawaki S.,
RA   Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H.,
RA   Haferlach T., Shirahige K., Miyano S., Ogawa S.;
RT   "Recurrent mutations in multiple components of the cohesin complex in
RT   myeloid neoplasms.";
RL   Nat. Genet. 45:1232-1237(2013).
//
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940-940(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//